Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > A Great Story

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Nov 11, 2022 10:19am

260 Views

Post# 35091264

RE:RE:A Great Story

Yoly900 wrote: You know everybody here waisting their time management has plan to squeeze corporation like a squeezed lemon. Whst ever happened to Canada approval before fda? You guys never mention this. Oh yeah Whst about tld1433 approval? NOT YET fkn joke bullshite 10 years with that 1433 bullshite big part scam. Whst about cannabis JV just didsapeared completely. Now we'll kill rest of this year and next they'll make it like we're delayed total scam til next year PS THE STOCK WILL HIT 0.37-0.45 than dump like a big shite in toilet that's all this is shiteee on toilet paper!

Just in case you are wondering: (Don't know anything about a JV)

Info only: (Another 90 day time frame from 10/21/2022 for next action to take place)

16/365,148 | T1081/20069:

METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF A CANNABINOID RECEPTOR AGONIST AND RADIATION THERAPY

Application type

Utility

Examiner

KARA RENITA MCMILLIAN

Group art unit

1627

Class/subclass

514/185.000

AIA (first inventor to file)

Yes

Entity status

Small

Earliest publication #

US 2019-0290657 A1

Earliest publication date

09/26/2019

Assignee for publication

-

Confirmation #

4146

Intl. registration # (Hague)

Intl. registration publication date

-

Correspondence address

3000 - CAESAR RIVISE, PC

7 Penn Center, 12th Floor

1635 Market Street

Philadelphia, PA

UNITED STATES

Inventors

Roger DUMOULIN-WHITE

Toronto (CA)
Arkady MANDEL

North York (CA)

Applicants

Theralase Technologies, Inc.

Toronto (CA)

Documents & transaction history

10/25/2022	CTNF	Non-Final Rejection	24	Preview	DOCX / PDF / PNG / XML
10/25/2022	SRFW	Search information including classification, databases and other search related notes	2	Preview	PDF
10/25/2022	SRNT	Examiner's search strategy and results	3	Preview	PDF
08/24/2022	SA..	Supplemental Response or Supplemental Amendment	1	Preview	PDF
08/24/2022	CLM	Claims	3	Preview	PDF / XML
08/24/2022	REM	Applicant Arguments/Remarks Made in an Amendment	3	Preview	PDF / XML
08/24/2022	REM	Applicant Arguments/Remarks Made in an Amendment	9	Preview	PDF / XML
08/24/2022	WFEE	Fee Worksheet (SB06)	2	Preview	PDF
08/24/2022	N417	Electronic Filing System(EFS) Acknowledgment Receipt	3	Preview	PDF